Skip to main content

Biomarin Pharmaceutical Inc Investor Event Transcript, Nov 17, 2026

Biomarin Pharmaceutical Inc (BMRN)

BioMarin said the Amicus acquisition closed in April, with Q3 the first quarter of combined results. It sees peak revenue of $1.4 billion for Gallifold and $1.2 billion for OpFolda. The company also noted pending FDA approval for Voxogo in hypochondroplasia. AI summary

Investor Event Transcript 2026-11-17 For: 2026-12-31
Added on November 18, 2026

Conference Transcript - BMRN 2026-11-17

Operator

Shortly, but I have the pleasure of introducing by Marin, Alexander, the CEO, and Brian, the CFO, who will give some introductory slides and remarks.

Alexander Hardy, CEO

Great. Thank you very much. We're going to have some fun without Akash here. So you'll have to tell him that we did a good job, you know, running the session without him. I just thought, you know, I'd just share just a few slides before we get in the Q&A that will also give Akash a bit of time to get over here. You know, it's three years now, first of December, since I joined Biomarin. We've made a lot of changes. I'm very excited about where the company is right now. And just these slides, well, I think will give you a good perspective of where we are. So, obviously, I'm going to be making forward-looking statements. You know, for those of you that don't know Biomarin, you know, we are a rare disease, global rare disease leader at scale. He made it. I made it. That's quite an entrance. Is there anything you want to say, or should I just keep going?

Akash, Analyst — J.P. Morgan

No, I almost got hit by a cab, but that's it. But yes, please go ahead. No, please start with intro remarks.

Alexander Hardy, CEO

Okay, good, good. Yep. So, you know, we're in 80 countries. Next year will be our 30th anniversary. We now have nine approved products, you know, five of them. In the metabolic condition space, six of them are first-in-disease treatments. This year, at the midpoint of our guidance, 3.8 to 3.9 billion will be a 20% growth. Out of those nine products, four of them, we believe, have the potential to be over a billion-dollar products. This is all. Built on a base of capabilities and global reach, which allows us, we believe, to continue to create enormous amounts of value for patients and for investors. You know, we have global capabilities end-to-end from research, development, regulatory, manufacturing, and obviously commercialization in that global footprint. And we're really experts at rare disease and finding patients and getting them started on the therapy and keeping them successfully on therapy and getting the benefits. I'm now going to hand over to Brian to go through just two slides on financial performance.

Brian Mueller, CFO

Thanks, Alexander. Biomaren's efforts to strengthen our financial profile over the last couple of years are showing up in our results. Using the midpoint of our 2026 revenue guidance, revenue is on track to grow approximately 60% over the last three years. Earnings per share has doubled. The middle panel here stops at 2025. I'll share that for 2026. There's a couple of acquisition-related in-process R&D charges coming through the financials, so we didn't show 2026 here. But if you look through those, our operational earnings per share over the three-year period is also on track to more than double. And that profitability is translating to cash flow, where our operating cash flow has increased by more than five times from 23 to 2025. And it's that strengthened cash flow performance that helped fund the amicus acquisition earlier this year, which brought to rare disease medicines. Gallifold for February disease and probability and up fold up for Pompe disease into our portfolio. The transaction closed in April, so Q3 was just our first quarter of the combined company results, and we showed that we can continue to add more patients to both of these therapies in BioMarin's hands. This acquisition was highly synergistic. We've identified approximately more than 50% of the non-GAAP operating costs as synergies in the combined business. This integration is operationally on track. We've already pulled forward two of our deleveraging and accretion metrics since closing the transaction earlier this year. Our views of peak revenue for Gallifold and Pombility and OpFolda are $1.4 billion and $1.2 billion, respectively. This is approximately a 40% and 20% respectively uplift on what some of the prior views of peak were, again, delivering upon the strategic rationale of this transaction. And again, with the synergies, we expect that by the end of this decade, Running the Amicus business on the BioMarin platform can generate operating margins of approximately 60%, and that cash flow is enabling us to reinvest in the business. I refer to this sometimes as a virtuous cycle where we believe we can both grow revenue and profitability and simultaneously invest in innovation, and I think we're showing that with some of the new additions to our pipeline this year. I'll hand it back to Alexander for that.

Alexander Hardy, CEO

Thanks, Brian. Yeah, so let me pick up with your virtuous cycle, Brian. You know, we're taking these at-scale, global, rare disease player, the capabilities we have here, together with that diversified growth profile and the financial strength that you just saw from Brian's presentation, and we're reinvesting it in growth. And we brought four pipeline products into our company in the last 12 months. And here are the four products, and no doubt, Akash, you're going to ask me a lot of questions about each one of these. We got BMN 820 as part of the Amicus acquisition. This is for FSGS, a very interesting indication. It's a phase three asset. We expect the readout in 2028. BMN 333 is an internal asset. It's our long-acting CNP. We're designing this to be, we believe, have the potential to be best in class in achondroplasia and hypochondroplasia, and importantly, it has a phase two readout in patients in 2027. Obviously, you're very familiar with the market size, 24,000 patients globally. And then BMN 440, we got this as part of the Lester acquisition. This will be the first oral treatment, we hope, in hypophosphatasia. So it's a very large, very large significant market of 35,000 patients. This is a lot more than an oral therapy in a market that is an injectable market. By being an oral therapy, we believe it can be systemically absorbed and address many of the issues that are currently not addressed by the current enzyme therapies.

Brian Mueller, CFO

In this disease.

Alexander Hardy, CEO

And then finally, we have BMN 450. This is our most recent acquisition, announced, what, two weeks ago now. This is potentially the first subcutaneous treatment for Fabray's disease. Obviously, this is a market we're already now in with Gallifold in Fabray disease. This allowed us to address a larger population, so not just the genetic amenable population. But again, this will be an important advance for patients as a subcutaneous therapy versus the injectable drugs. So these are four very important pipeline drugs. Let's now talk about, with the final slide, you know, as I say, many, many important catalysts in the coming period. So looking ahead to the remainder of this year in 27 and into 28, we have the pending FDA approval of Voxogo in hypochondroplasia. This will be, and we're very proud of these milestones, this will be our seventh first in disease treatment if we're approved. It's also in front of Europe, and we're potentially also launching it around the world in multiple countries next year. We have the phase two results of 333, the long-acting CNP. We also have the first patient data for BMN 440, the drug I talked about in hypophosphatasia. So we've got a lot of very, very important milestones coming up in clinical catalysts, together with obviously the ongoing financial strength and growth of our underlying business. And with that, Akash, over to you.

Akash, Analyst — J.P. Morgan

I appreciate it. And thanks so much for the intro remarks. So I'm going to, you know... You got into your tenure at Beimer, and I think you, I could notice how thoughtful you were. You took time to really listen to what shareholders wanted. You assessed the company internally. You moved into kind of a business unit structure. And I have to give you credit. I mean, if you look at the margin profile of the company, it's materially improved on your tenure. We haven't necessarily seen maybe the stock reflect the operational changes that you've incorporated. And I think the question that I get as an analyst and I struggle with, and I'm sure you do as well, which is, what do I have to show you guys to give us credit for what we're building here? So kind of reverse engineer that problem. Because I'm sure you have this discussion from a strategic perspective with a board perspective. What have you heard from investors over the last couple of years in your tenure about what we want out of BuyMarin? And what do you think you'd be able to show in 2027 to really start getting credit from a stock price perspective?

Alexander Hardy, CEO

Yeah, absolutely. I mean, first and foremost, and I'm not just saying this as a leadership team and a board, you know, we're focused on things that we believe are driving fundamental long-term value creation. And we've made a lot of changes, which I think unambiguously have created a lot of value. They have not yet been appreciated by the external market. You know, I think quite clearly, and no doubt we're going to talk about this, it's the competitive overhang on Vox Ogo. Where we have two competitors, one, as you well know, has launched about three quarters ago, and one is pending approval. You know, I think that has been totally blown out of context in terms of its impact on Biomarin's future growth. You know, if you look at Voxogo in achondroplasia, which is the indication currently under competition in the United States, that's only 6% of our revenue. And we do not expect to lose that business. We will have the infant indication advantage for several more years, which is where the majority of patients started around the world. And in addition, you know, this plays into this 80-country global footprint that we talked about. 75% of our revenue with Voxogo is outside the United States. So, you know, this has been, you know, part of the theme. The other part of the theme has been, well, okay, we see the value that you're creating. We think, and I don't want to be immodest. Here I am in London. I feel like I really shouldn't be immodest in London. This is the British part of me. But people say, you know, we like the decisions, the speed of the decisions. We like the execution. But why now? Why do we have to buy now? What are the catalysts? And I think you can see now that we have taken this financial performance and built a really compelling pipeline of drugs, which are completely on strategy. These are, as you can see, really fit into our expertise in genetic conditions. They drop really right into most of them drop right into those business units we set up of skeletal conditions and metabolic conditions. And we're now in a situation where we've got these. We're a bit more like your classic U.S. biotech, where we have this pipeline. And welcome to the call. Start to resonate with folks.

Akash, Analyst — J.P. Morgan

Understood. You know, it's been interesting. You look at companies like AppV or J&J, like they've had massive moves. I know that's a large cap pharma, but you would hear investors and you would say this company has tremendous earnings visibility. And it's interesting, even if you look at some of the rotation into large cap biotech now, the number one predictor of stock performance seems to be positive estimate earnings revisions going into next year. I feel like there is that potential for Bymarin, right? Whether it's stability on Voxoga, whether it's the amicus integration and really how quickly that can get done. But that also gets into this kind of interesting question of, well, how do we get guidance right? Right? Like, so... Guide people towards what we're really excited about, the financial profile, but also make sure that we're able to deliver on that, if not more. So what did we learn maybe from last year with some of the moving parts within the product portfolio? How de-risk is that as we get into next year? And again, what's the view of guidance for Biomarin under your tenure now? Do you want to handle this, Brian?

Brian Mueller, CFO

I'll start, and then you can bring it back up to a higher level. Yeah, so first of all, on execution, we've been executing, Akash. We've got, with the third quarter, 15 consecutive quarters of beating consensus on non-GAAP earnings per share, which is our primary operating measure. We also have a strong track record of delivering, if not over-delivering, on revenue. We adjusted our Q3 guidance because of timing of a basket of orders from a single large international market. The 80-country footprint that Alexander referred to is two-thirds outside of the U.S. Most of these Biomarin customers are single national payer health care systems, and they tend to order infrequently and sometimes with some volatility. So between Q2 and Q3, that customer shared with us that they wanted to defer some orders from planned in Q4 to early 27. So that was just a mere timing shift, normal part of our business. But this late in the year, it was difficult to find the offsets. And in terms of portfolio shifts, you might be referring to Rocktavian. And, you know, that was... A challenging journey, but we think we made the right business decisions for both the value of the business going forward and the focus of the business to deliver value to shareholders. We think we've largely moved past that now, and now we're focusing on executing the strategy that you saw us summarized today.

Akash, Analyst — J.P. Morgan

Understood. Now, maybe going in into your pipeline, and I always find this a bit curious, 333. I'm looking forward to. I think there's a shot that your team can show superiority. But look, it's preclinical data. You know, the biology is TBD. And I think your team openly acknowledges that. But I feel like there's a faulty investor perception that, well, they're going for superiority. And if they can't get for superiority, there's no way they can power a study for non-inferiority because it takes so many patients. Ergo. 333 may not move forward. And for me, I think, look, worst case scenario, you have a weekly option. You're already in a leadership position in achondroplasia, and having more options for patients has never been the wrong thing. Can we address, like, address that directly? Let's say that we get the phase two data next year, and we don't feel confident in your team that you can show superiority. Does that mean that there isn't a path forward with 333 in your product portfolio? Or is that perception incorrect?

Alexander Hardy, CEO

You know, I'll answer the question in a couple of different ways. I mean, you know, we are convinced that we've got the right drug to do this experiment. We also believe that the lane is open for a drug that offers superiority. There's nothing that so far has bested. Voxogo from an efficacy standpoint, and actually from the evidence, you know, beyond height in terms of efficacy. So we think the lane is open. We think this is the right molecule. In the phase one healthy volunteer data, we far exceeded what we were hoping to see in terms of free CNP levels over and above what our competitor, the other long-acting CNP, has demonstrated. And we've taken into the phase two. Three dosages that offered between three and eight times the level of free CNP than the competitor's long-acting drug. But now the experiment needs to be done to say, does that PK translate through to additional growth? We think that we have a good reason to believe that's the case, but now we need to see the experiment. So we are designing, and we have designed, and we have FDA support for a seamless operational phase two, phase three design with a superiority endpoint, because that's what we believe the market really wants. That's what we believe will result in a best-in-class therapy, together with a longer dosing interval of a week. Now, we will look at that phase two data, and it won't just be the phase two data that comes out of the 40 patients in that study, but using really drawing upon the wealth of data we have from the Voxerga and the natural history studies, and we will determine kind of what the path forward is. But our plan A, plan B, plan C is superiority. We could look at those results and go, you know what, we may go take a different path. You know, if you're looking at a two-sided non-inferiority study, it's a large study, but we could do a one-sided non-inferiority study. But I would not get ahead of ourselves. Our goal is superiority.

Akash, Analyst — J.P. Morgan

Understood. But at least there is an option available. Okay, that makes sense. Now, going into kind of your pipeline assets, and, you know, it's, to me, I always think with a question, well, when does the stock really work? I think To your credit, Alexander, a lot of the beauty you've done is going to be highly accretive because you've already built a commercial foothold in some of these markets, especially with your recent deal as a Gallifold add-on. Some of them are more even aspirations. I mean, hypophosphatemia, that's one of the biggest markets. Even, you know, Astra will talk about that, but that might take some more time to really figure out. So, when you think about your pipeline, divide it up into kind of two buckets. We feel very confident on the biology. We think this is scientifically de-risk. Maybe not the biggest market opportunity, but it's highly synergistic to what we have. And then here's our kind of longer-term bets where it's aspirational, but man, if we're right, it's a home run, right? So you talked about four assets, you have even more in your in your pipeline. But like if you were to put it through that lens. What's the low-hanging de-risk fruit versus the aspirational bets for you?

Alexander Hardy, CEO

Yeah. It's an interesting way of looking at it, and I would say we've already talked about 333. We know that space. As I say, we are using all of our experience and our expertise and our data to be able to really, I think, develop that program to the optimal level. I would probably say that at 450, which is, this is the subcutaneous treatment for Fabray disease, you know, this is a space that we already, you know, have some level of expertise in that we got as part of the amicus acquisition. You know, it's a subcutaneous treatment for Fabray, allows us to, again, address a larger population. I think that is, you know, kind of pretty straightforward and that, you know, the data that we've already seen there gives us confidence that this looks like a really good drug. Then I think we've got 440. Now, it is a large, it's a large indication. AstraZeneca talks about the potential for 1850 as being between three to five billion. We're not in a situation here where we're going to be predicting what the potential could be, but I think the prospect of a small molecule, again, is really interesting. It clearly is much more than a patient convenience advantage, such as infragratinib versus Foxogo in achondroplasia. This potentially could allow us to address... morbidity associated with hyperphosphatase in a way that both Strenzik and 1850, that 1850 is the follow-on molecule that AstraZeneca is developing, has not been able to address. And then on top of it, we think we have... Blue ocean, open water, whatever phrase you use, with the adult onset population, where 1850 had negative trial data. Again, as an oral, where you can penetrate the muscle as opposed to bone penetrant with an enzyme therapy, we think it gives us the potential to be able to maybe open up that indication. Now, probably be a different study is the endpoints will be different. But this is the work that we can do. And we like to bring these programs in at this stage, because it gives us a chance to To really shape the development program and invest at the level that these programs really require. The last one I'll mention is it's 820 FSGS. I mean, it's a large indication. There's a significant unmet need there. We think this is a differentiated molecule. So it's a CCR2 inhibitor. So it works in a different way than Trevere's Phil Spari. It potentially won't have the same restricted indication in terms of nephrotic status and potentially not have the safety monitoring requirement. That's a it's a very large disease, but I would say, you know, this is this is one where we fully. Enrolled the study. We have the US rights. We've fully enrolled the study. We just have to wait now for the readout. And so it's a little harder to kind of assess what the likelihood of that is. But this wasn't central to our thesis with buying Amicus. We could justify, as Brian alluded to, the Amicus acquisition purely on the Gallifold and POMOP opportunity on the revenue synergy side, the 1.4 and the 1.2 billion, together with the synergies on the expense side. We got... Really, 820 is a bonus, and we think that's an interesting option, but we'll have to see what that readout looks like in 2028. I mean, the endpoint is de-risked proteinuria, so we also are pleased to see that. We have a two-year proteinuria primary endpoint, and there is precedent for that to be approvable.

Akash, Analyst — J.P. Morgan

Understood. Last question is more from a strategic perspective. And then also, like, again, investors may not get it. Counterparties might. I mean, you have, again, there used to be a debate about what the margin profile of by Marin actually could be. I mean, you're now approaching. Earnings margins growth that would rival any kind of mid cap commercial biotech in some instances exceeded. And that's always been kind of a common critique is, you know. We don't know when this company will become profitable. I feel like you've really you've answered that question. Investors don't get it. Do you feel like when you talk with strategics, when you talk with partners who are interested in tapping into your platform, that there is a growing appreciation of what you've built? Like, do you feel like there is a widening disconnect between investor perception and strategic perception of Bymarin right now?

Alexander Hardy, CEO

You know, I think we're in a very good situation, given the financial strength of the company and the profile and the capabilities that we've been able to build over 30 years. And to be in rare diseases and genetic conditions when we don't have time to get into this, but genetic conditions with advanced analytics and AI, there's so much potential there. And also in an increasingly complex world with pharma political issues and pricing issues, rare disease is a really great space to be in. The strategics aren't particularly focused on rare disease. And this is a great position for Biomarin to be in as an at-scale leader in rare diseases. So, we are able to build our pipeline, leverage our capabilities. We are not... Competing with the strategics for these assets, and we can now compete most of the smaller rare disease companies, given our scale and our financial resources. So I don't think I should probably come to Jeffrey's and tell the strategics here, but they are focused on these. Highly prevalent populations. And I hope they leave us in rare disease to create an enormous amount of value for both patients and for investors.

Akash, Analyst — J.P. Morgan

Understood. Hey, thank you so much. I really do appreciate it.